{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:06:38Z","timestamp":1789239998811,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case Presentation<\/jats:title>\n                <jats:p>We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48\u00a0h, followed by the administration of a single dose of sublingual buprenorphine\/naloxone and then extended-release subcutaneous buprenorphine. The patients did not experience precipitated withdrawal and only had mild withdrawal symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00479-1","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:46:42Z","timestamp":1718682402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8054-6911","authenticated-orcid":false,"given":"Pouya","family":"Azar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Schneiderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Barron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S. H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayyon","family":"Newman-Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matin","family":"Narimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha J.","family":"Ignaszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickie","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard M.","family":"Krausz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil R.","family":"Maharaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"issue":"5","key":"479_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","volume":"69","author":"JS Orman","year":"2009","unstructured":"Orman JS, Keating GM. Buprenorphine naloxone. Drugs. 2009;69(5):577\u2013607.","journal-title":"Drugs"},{"issue":"1","key":"479_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4103\/0976-3147.91934","volume":"3","author":"P Whelan","year":"2012","unstructured":"Whelan P, Remski K. Buprenorphine vs methadone treatment: a review of evidence in both developed and developing worlds. J Neurosci Rural Pract. 2012;3(1):45\u201350.","journal-title":"J Neurosci Rural Pract"},{"issue":"5","key":"479_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40261-021-01032-7","volume":"41","author":"JP De Aquino","year":"2021","unstructured":"De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clin Drug Investig. 2021;41(5):425.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"479_CR4","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/02791072.2014.921743","volume":"46","author":"C Teruya","year":"2014","unstructured":"Teruya C, Schwartz RP, Mitchell SG, Hasson AL, Thomas C, Buoncristiani SH, et al. Patient perspectives on buprenorphine\/naloxone: a qualitative study of retention during the starting treatment with agonist replacement therapies (START) study. J Psychoact Drugs. 2014;46(5):412\u201326.","journal-title":"J Psychoact Drugs"},{"key":"479_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/SAR.S109919","volume":"7","author":"R H\u00e4mmig","year":"2016","unstructured":"H\u00e4mmig R, Kemter A, Strasser J, von Bardeleben U, Gugger B, Walter M, et al. Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method. Subst Abuse Rehabil. 2016;7:99\u2013105.","journal-title":"Subst Abuse Rehabil"},{"issue":"1","key":"479_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13722-021-00220-2","volume":"16","author":"JSH Wong","year":"2021","unstructured":"Wong JSH, Nikoo M, Westenberg JN, Suen JG, Wong JYC, Krausz RM, et al. Comparing rapid micro-induction and standard induction of buprenorphine\/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021;16(1):1\u201310.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"479_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/ajad.13050","volume":"29","author":"P Azar","year":"2020","unstructured":"Azar P, Wong JSH, Jassemi S, Moore E, Vo DX, Nikoo M, et al. A Case Report: Rapid Micro-induction of Buprenorphine\/Naloxone to administer Buprenorphine extended-release in an adolescent with severe opioid use disorder. Am J Addict. 2020;29(6):531\u20135.","journal-title":"Am J Addict"},{"issue":"6","key":"479_CR8","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/15563650.2022.2028802","volume":"60","author":"K Baumgartner","year":"2022","unstructured":"Baumgartner K, Salmo E, Liss D, Devgun J, Mullins M, Galati B, et al. Transdermal buprenorphine for in-hospital transition from full agonist opioids to sublingual buprenorphine: a retrospective observational cohort study. Clin Toxicol (Phila). 2022;60(6):688\u201393.","journal-title":"Clin Toxicol (Phila)"},{"issue":"5","key":"479_CR9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/j.1521-0391.2011.00159.x","volume":"20","author":"M Hess","year":"2011","unstructured":"Hess M, Boesch L, Leisinger R, Stohler R. Transdermal Buprenorphine to switch patients from higher dose methadone to buprenorphine without severe withdrawal symptoms. Am J Addict. 2011;20(5):480\u20131.","journal-title":"Am J Addict"},{"key":"479_CR10","doi-asserted-by":"crossref","unstructured":"Azar P, Wong JSH, Mathew N, Vogel M, Perrone J et al. 48-hour induction of Transdermal Buprenorphine to Sublingual Buprenorphine\/Naloxone: the IPPAS Method. J Addict Med. 2022.","DOI":"10.1097\/ADM.0000000000001072"},{"issue":"4","key":"479_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ajad.12869","volume":"28","author":"S Klaire","year":"2019","unstructured":"Klaire S, Zivanovic R, Barbic SP, Sandhu R, Mathew N, Azar P. Rapid micro-induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series. Am J Addict. 2019;28(4):262\u20135.","journal-title":"Am J Addict"},{"key":"479_CR12","doi-asserted-by":"publisher","unstructured":"Marsden J, Kelleher M, Gilvarry E, et al. Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial. eClinicalMedicine. 2023;66. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102311.","DOI":"10.1016\/j.eclinm.2023.102311"},{"key":"479_CR13","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1093\/pm\/pnx235","volume":"19","author":"T Priestley","year":"2018","unstructured":"Priestley T, et al. Converting from Transdermal to Buccal formulations of Buprenorphine: a pharmacokinetic Meta-model Simulation in healthy volunteers. Pain Med. 2018;19:1988\u201396.","journal-title":"Pain Med"},{"key":"479_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40262-020-00957-0","volume":"60","author":"AK Jones","year":"2021","unstructured":"Jones AK, Ngaimisi E, Gopalakrishnan M, Young MA, Laffont CM. Population Pharmacokinetics of a monthly Buprenorphine Depot Injection for the treatment of opioid use disorder: a combined analysis of phase II and phase III trials. Clin Pharmacokinet. 2021;60:527\u201340.","journal-title":"Clin Pharmacokinet"},{"key":"479_CR15","unstructured":"RxODE: Facilities for Simulating from ODE-Based Models. R package version 1.1.5. 2022. https:\/\/cran.r-project.org\/web\/packages\/RxODE\/index.html."},{"issue":"2","key":"479_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/02791072.2003.10400007","volume":"35","author":"DR Wesson","year":"2003","unstructured":"Wesson DR, Ling W. The clinical opiate Withdrawal Scale (COWS). J Psychoact Drugs. 2003;35(2):253\u20139.","journal-title":"J Psychoact Drugs"},{"issue":"3","key":"479_CR17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1001\/jama.2016.9382","volume":"316","author":"RN Rosenthal","year":"2016","unstructured":"Rosenthal RN, Lofwall MR, Kim S, et al. Effect of Buprenorphine implants on Illicit Opioid Use among abstinent adults with opioid dependence treated with Sublingual Buprenorphine: a Randomized Clinical Trial. JAMA. 2016;316(3):282\u201390.","journal-title":"JAMA"},{"issue":"5","key":"479_CR18","doi-asserted-by":"publisher","first-page":"e219041","DOI":"10.1001\/jamanetworkopen.2021.9041","volume":"4","author":"N Lintzeris","year":"2021","unstructured":"Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Tiberg F. Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial. JAMA Netw Open. 2021;4(5):e219041\u2013219041.","journal-title":"JAMA Netw Open"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00479-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00479-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00479-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T07:03:36Z","timestamp":1727852616000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00479-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["479"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00479-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was waived as a case series of fewer than three patients are not subjected to review by our ethics board. Both patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Pouya Azar is a consultant on Indivior-led buprenorphine extended-release studies, which are unrelated to this case report. All other authors report no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}